

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 01011)

**DELAY IN DESPATCH OF CIRCULAR
IN RELATION TO THE VERY SUBSTANTIAL DISPOSAL AND
THE VERY SUBSTANTIAL ACQUISITION**

Reference is made to the announcement (the “**Announcement**”) of China NT Pharma Group Company Limited (the “**Company**”) dated 27 April 2020 in relation to, among others, the very substantial disposal of the proposed disposal of the entire issued share capital of NT Pharma International and the very substantial acquisition of the proposed acquisition of 40% equity interests in Kangchen. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As stated in the Announcement, the Circular containing, among other things, (i) further details on the Transaction Documents and the transactions contemplated thereunder; (ii) the valuation report of NT Pharma International; (iii) the valuation report of Kangchen; and (iv) a notice convening the EGM as well as other information required to be disclosed under the Listing Rules was expected to be despatched to the Shareholders on or before 20 May 2020.

As additional time is required for finalising certain information to be included in the Circular, the Company expects that the despatch date of the Circular will be delayed to a date falling on or before 10 June 2020.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 20 May 2020

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Tze Shan Hailson Yu, Mr. Pan Fei and Dr. Zhao Yubiao.